FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150023617> ?p ?o ?g. }

• W2150023617 endingPage "2216" @default.
• W2150023617 startingPage "2201" @default.
• W2150023617 abstract "Anaemia is frequently diagnosed in patients with cancer, yet it is difficult to identify a single cause due to its multifactorial aetiology. We conducted a systematic literature review (1996–2003) to produce evidence-based guidelines on the use of erythropoietic proteins in anaemic patients with cancer (see Table 4). Level I evidence exists for a positive impact of erythropoietic proteins on haemoglobin (Hb) levels when administered to patients with chemotherapy-induced anaemia or anaemia of chronic disease, when used to prevent cancer anaemia, in patients undergoing cancer surgery and following allogeneic bone marrow transplantation. The Hb level at which erythropoietic protein therapy should be initiated is difficult to determine as it varied between studies; a large number of Level I studies in patients with chemotherapy-induced anaemia or anaemia of chronic disease enrolled patients with a Hb concentration ⩽105 g/L, but none compared the effect of different baseline Hb levels on the response to treatment. Similarly, several studies defined the target Hb concentration as 120–130 g/L following treatment with erythropoietic proteins, but none specifically addressed the correlation between target Hb level and clinical benefit in a randomised fashion. Level I evidence shows that red blood cell (RBC) transfusion requirements are significantly reduced with erythropoietic protein therapy in patients with chemotherapy-induced anaemia or when used to prevent cancer anaemia (approximately 20% reduction compared with controls). We found indirect Level I and III evidence that patients with chemotherapy-induced anaemia or anaemia of chronic disease initially classified as non-responders to standard doses proceed to respond to treatment following a dose increase (absolute increases in response rate ranged from 8% to 18%). However, none of these studies examined the effect on response rates of a longer treatment period at the lower dose, or performed a randomised comparison of a dose increase versus an unchanged dose. There is Level I evidence to show that quality-of-life (QOL) is significantly improved in patients with chemotherapy-induced anaemia and in those with anaemia of chronic disease, particularly in patients achieving a Hb response to erythropoietic protein therapy. There are insufficient data to determine the effect on survival following treatment with erythropoietic proteins in conjunction with chemotherapy or radiotherapy. There is Level I evidence that dosing of erythropoietic proteins less frequently than three times per week (TIW) is efficacious when used to treat chemotherapy-induced anaemia or prevent cancer anaemia. There is Level III evidence that initial doses of erythropoietic proteins considered to be higher than current standard practice produce higher haematological responses in patients with chemotherapy-induced anaemia or anaemia of chronic disease. Level I evidence demonstrates that several baseline patient parameters (e.g., low endogenous erythropoietin [EPO] concentration, age <60 years, Hb concentration ⩾90 g/L) impact upon the response to erythropoietic proteins when used to treat chemotherapy-induced anaemia or prevent cancer anaemia. Evidence indicates that endogenous EPO concentration impacts on response in patients with lymphoproliferative malignancies, but is not a valid parameter in patients with solid tumours. There is Level I evidence that fixed doses of erythropoietic proteins can be used at the start of therapy to treat patients with chemotherapy-induced anaemia, but maintenance doses should be titrated individually. There is no evidence that pure red cell aplasia (PRCA) occurs following treatment with erythropoietic proteins in patients with chemotherapy-induced anaemia or when used prophylactically in patients with cancer. There is Level I evidence that the risk of thromboembolic events and hypertension are slightly elevated in patients with chemotherapy-induced anaemia receiving erythropoietic proteins. Level I evidence supports the effectiveness of erythropoietic proteins to prevent anaemia in non-anaemic cancer patients receiving chemotherapy or radiotherapy or in those undergoing cancer surgery. However, these are non-licensed indications and we do not currently recommend the prophylactic use of erythropoietic proteins to prevent anaemia in patients who have normal Hb values at the start of treatment. Additional trials are warranted, especially on the issues of iron replacement and cost-effectiveness of erythropoietic protein therapy, as well as on tumour response/progression and survival." @default.
• W2150023617 created "2016-06-24" @default.
• W2150023617 creator A5025326688 @default.
• W2150023617 creator A5033285318 @default.
• W2150023617 creator A5045932644 @default.
• W2150023617 creator A5049924304 @default.
• W2150023617 creator A5059745295 @default.
• W2150023617 creator A5064036697 @default.
• W2150023617 creator A5068111941 @default.
• W2150023617 creator A5078383767 @default.
• W2150023617 date "2004-10-01" @default.
• W2150023617 modified "2023-10-17" @default.
• W2150023617 title "EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer" @default.
• W2150023617 cites W1608757922 @default.
• W2150023617 cites W1884165293 @default.
• W2150023617 cites W1885881044 @default.
• W2150023617 cites W1888844917 @default.
• W2150023617 cites W1939178279 @default.
• W2150023617 cites W1966614057 @default.
• W2150023617 cites W1968196100 @default.
• W2150023617 cites W1970997581 @default.
• W2150023617 cites W1971734795 @default.
• W2150023617 cites W1987307200 @default.
• W2150023617 cites W1989040372 @default.
• W2150023617 cites W1991284991 @default.
• W2150023617 cites W1991915227 @default.
• W2150023617 cites W1996698172 @default.
• W2150023617 cites W1996927047 @default.
• W2150023617 cites W2002189627 @default.
• W2150023617 cites W2002395765 @default.
• W2150023617 cites W2004967129 @default.
• W2150023617 cites W2005893164 @default.
• W2150023617 cites W2007313133 @default.
• W2150023617 cites W2009677160 @default.
• W2150023617 cites W2011196639 @default.
• W2150023617 cites W2012264968 @default.
• W2150023617 cites W2019289959 @default.
• W2150023617 cites W2020658869 @default.
• W2150023617 cites W2021827603 @default.
• W2150023617 cites W2025740171 @default.
• W2150023617 cites W2029738096 @default.
• W2150023617 cites W2030211882 @default.
• W2150023617 cites W2037347063 @default.
• W2150023617 cites W2040533210 @default.
• W2150023617 cites W2052311638 @default.
• W2150023617 cites W2053446329 @default.
• W2150023617 cites W2057170780 @default.
• W2150023617 cites W2060861099 @default.
• W2150023617 cites W2063440159 @default.
• W2150023617 cites W2081203495 @default.
• W2150023617 cites W2086437884 @default.
• W2150023617 cites W2088504665 @default.
• W2150023617 cites W2091061603 @default.
• W2150023617 cites W2093666912 @default.
• W2150023617 cites W2093815200 @default.
• W2150023617 cites W2099009106 @default.
• W2150023617 cites W2107260099 @default.
• W2150023617 cites W2123347304 @default.
• W2150023617 cites W2130028945 @default.
• W2150023617 cites W2138431636 @default.
• W2150023617 cites W2140941208 @default.
• W2150023617 cites W2146353390 @default.
• W2150023617 cites W2155080102 @default.
• W2150023617 cites W2158228942 @default.
• W2150023617 cites W2159283488 @default.
• W2150023617 cites W2162295328 @default.
• W2150023617 cites W2329804409 @default.
• W2150023617 cites W2601846828 @default.
• W2150023617 cites W269470825 @default.
• W2150023617 cites W4139115 @default.
• W2150023617 cites W4240197418 @default.
• W2150023617 cites W4251142319 @default.
• W2150023617 cites W4253440008 @default.
• W2150023617 cites W53850359 @default.
• W2150023617 doi "https://doi.org/10.1016/j.ejca.2004.07.015" @default.
• W2150023617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15454245" @default.
• W2150023617 hasPublicationYear "2004" @default.
• W2150023617 type Work @default.
• W2150023617 sameAs 2150023617 @default.
• W2150023617 citedByCount "277" @default.
• W2150023617 countsByYear W21500236172012 @default.
• W2150023617 countsByYear W21500236172013 @default.
• W2150023617 countsByYear W21500236172014 @default.
• W2150023617 countsByYear W21500236172015 @default.
• W2150023617 countsByYear W21500236172016 @default.
• W2150023617 countsByYear W21500236172017 @default.
• W2150023617 countsByYear W21500236172018 @default.
• W2150023617 countsByYear W21500236172019 @default.
• W2150023617 countsByYear W21500236172020 @default.
• W2150023617 countsByYear W21500236172021 @default.
• W2150023617 countsByYear W21500236172022 @default.
• W2150023617 countsByYear W21500236172023 @default.
• W2150023617 crossrefType "journal-article" @default.
• W2150023617 hasAuthorship W2150023617A5025326688 @default.
• W2150023617 hasAuthorship W2150023617A5033285318 @default.
• W2150023617 hasAuthorship W2150023617A5045932644 @default.
• W2150023617 hasAuthorship W2150023617A5049924304 @default.
• W2150023617 hasAuthorship W2150023617A5059745295 @default.

• next